Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.

Article  PubMed  Google Scholar 

Jiang D, Qiu T, Peng J, Li S, Tala, Ren W, et al. YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer. Cell Death Differ. 2022;29:1283–95.

Article  PubMed  PubMed Central  Google Scholar 

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90.

Article  PubMed  PubMed Central  Google Scholar 

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32.

Article  PubMed  Google Scholar 

Wang F, Luo M, Qu H, Cheng Y. BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1. FEBS Open Bio. 2021;11:1497–503.

Article  PubMed  PubMed Central  Google Scholar 

Wei W, Chen W, He N. HDAC4 induces the development of asthma by increasing Slug-upregulated CXCL12 expression through KLF5 deacetylation. J Transl Med. 2021;19:258.

Article  PubMed  PubMed Central  Google Scholar 

Su A, Yao K, Zhang H, Wang Y, Zhang H, Tang J. DANCR induces cisplatin resistance of triple-negative breast cancer by KLF5/p27 signaling. Am J Pathol. 2023;193:248–58.

Article  PubMed  Google Scholar 

Chen P, Qian XK, Zhang YF, Sun XG, Shi XJ, Gao YS. KLF5 promotes proliferation in gastric cancer via regulating p21 and CDK4. Eur Rev Med Pharm Sci. 2020;24:4224–31.

Google Scholar 

Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W, et al. Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression. Theranostics. 2016;6:533–44.

Article  PubMed  PubMed Central  Google Scholar 

Shi P, Liu W, Tala, Wang H, Li F, Zhang H, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017;3:17010.

Article  PubMed  PubMed Central  Google Scholar 

Liu R, Zhi X, Zhou Z, Zhang H, Yang R, Zou T, et al. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Kruppel-like factor 5 transcription by Sp1. Sci Rep. 2018;8:1138.

Article  PubMed  PubMed Central  Google Scholar 

Chen CH, Yang N, Zhang Y, Ding J, Zhang W, Liu R, et al. Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers. Int J Biol Sci. 2019;15:1733–42.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Qiu T, Wu Y, Yang C, Li Y, Du G, et al. Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer. Cell Death Differ. 2021;28:2931–45.

Article  PubMed  PubMed Central  Google Scholar 

Kong Y, Ren W, Fang H, Shah NA, Shi Y, You D, et al. Histone deacetylase inhibitors (HDACi) promote KLF5 ubiquitination and degradation in basal-like breast cancer. Int J Biol Sci. 2022;18:2104–15.

Article  PubMed  PubMed Central  Google Scholar 

Tung CH, Huang MF, Liang CH, Wu YY, Wu JE, Hsu CL, et al. alpha-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer. Theranostics. 2022;12:1173–86.

Article  PubMed  PubMed Central  Google Scholar 

Luan Y, Wang P. FBW7-mediated ubiquitination and degradation of KLF5. World J Biol Chem. 2014;5:216–23.

Article  PubMed  PubMed Central  Google Scholar 

Luo Y, Chen C. The roles and regulation of the KLF5 transcription factor in cancers. Cancer Sci. 2021;112:2097–117.

Article  PubMed  PubMed Central  Google Scholar 

Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G, et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat Commun. 2015;6:8471.

Article  PubMed  Google Scholar 

Wu Y, Qin J, Li F, Yang C, Li Z, Zhou Z, et al. USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5. J Biol Chem. 2019;294:17837–47.

Article  PubMed  PubMed Central  Google Scholar 

Zhang T, Su F, Wang B, Liu L, Lu Y, Su H, et al. Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma. Oncogene. 2024;43:1190–202.

Article  PubMed  Google Scholar 

Yue X, Liu T, Wang X, Wu W, Wen G, Yi Y, et al. Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1-BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy. Acta Pharm Sin B. 2023;13:3382–99.

Article  PubMed  PubMed Central  Google Scholar 

Thomas JF, Valencia-Sanchez MI, Tamburri S, Gloor SL, Rustichelli S, Godinez-Lopez V, et al. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1. Sci Adv. 2023;9:eadg9832.

Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 2009;284:34179–88.

Article  PubMed  PubMed Central  Google Scholar 

Xia YK, Zeng YR, Zhang ML, Liu P, Liu F, Zhang H, et al. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network. Protein Cell. 2021;12:557–77.

Article  PubMed  Google Scholar 

Ishii Y, Kolluri KK, Pennycuick A, Zhang X, Nigro E, Alrifai D, et al. BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. J Biol Chem. 2021;297:101223.

Article  PubMed  PubMed Central  Google Scholar 

Campagne A, Lee MK, Zielinski D, Michaud A, Le Corre S, Dingli F, et al. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat Commun. 2019;10:348.

Article  PubMed  PubMed Central  Google Scholar 

Mashtalir N, Daou S, Barbour H, Sen NN, Gagnon J, Hammond-Martel I, et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol Cell. 2014;54:392–406.

Article  PubMed  Google Scholar 

Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153–9.

Article  PubMed  PubMed Central  Google Scholar 

Kang M, Park SG, Lee SA, Kim S, Lee D, Shirbhate ME, et al. Targeting BAP1 with small compound inhibitor for colon cancer treatment. Sci Rep. 2023;13:2264.

Article  PubMed  PubMed Central  Google Scholar 

Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, et al. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma. Lung Cancer. 2019;127:164–6.

Article  PubMed  Google Scholar 

Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, et al. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021;2:515–26.

Article  PubMed  Google Scholar 

Tsuboyama N, Wang R, Szczepanski AP, Chen H, Zhao Z, Shi L, et al. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer. Oncogene. 2022;41:2152–62.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen J, Mi D, Ling J, Li H, He P, et al. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway. Cancer Lett. 2023;560:216142.

Article  PubMed  Google Scholar 

Tang Y, Wang X, Li Z, He Z, Yang X, Cheng X, et al. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021;54:454–67.e6.